Steven et al (134) found that GLP-1RAs activated GLP-1Rs in platelets via a cAMP/PKA-dependent mechanism, mitigating endotoxemia-induced microvascular thrombosis and mortality, thereby preventing systemic inflammation, vascular dysfunction and end-organ damage
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide (October 17, 2024) Tirzepatide And Muscle Composition Changes In People With Type 2 Diabetes (SURPASS-3 MRI): A Post-Hoc Analysis Of A Randomised, Open-Label, Parallel-Group, Phase 3 Trial (April 30, 2025) Changes In Lean Body Mass With Glucagon-Like Peptide-1-Based Therapies And Mitigation Strategies (June 27, 2024) Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (July 8, 2025) WEGOVY (semaglutide) Prescribing Information (November 2024)
Gomisin N) or schisandrol B (47)
However, recent insights suggest that the gut and brain GLP-1 systems operate largely independently with mRNA transcripts for proglucagon (GCG), the precursor peptide for GLP-1, being abundant in the brainstem, particularly within the nucleus tractus solitarius (NTS
